Bioplatforms in 2025

Bioplatforms, enablers et al. So, NFX’s point on biotechs is: having an candidate in trials is good, BUT having a pipeline is even better. Why? Pipeline is an asset that can produce candidates in your area of focus (say, Alzheimer’s antibodies) ...